Christopher Cline compensation by year
Travere Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $466,667 | $497,500 | $522,917 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $604,800 | $299,155 | $583,110 |
| Option awards | $656,747 | $342,258 | $738,247 |
| Non-equity incentive | $230,300 | $350,000 | $393,750 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $12,976 | $12,607 | $12,890 |
| Total | $1,971,490 | $1,501,520 | $2,250,914 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed April 6, 2026, accession 0001438533-26-000027, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 21,500 | $821,515 | — |
| RSU | 18,750 | $716,438 | — |
| RSU | 10,125 | $386,876 | — |
| RSU | 8,500 | $324,785 | — |
| RSU | 7,000 | $267,470 | — |
| RSU | 4,920 | $187,993 | — |
| RSU | 2,188 | $83,603 | — |
| RSU | 1,250 | $47,763 | — |
| RSU | 125 | $4,776 | — |
| Option | 365 | — | $27.50 |
| Option | 58,000 | — | $20.46 |
| Option | 33,855 | — | $8.93 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Travere Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
Insider transactions since the last proxy
17 Form 4 lines since the FY2025 proxy (filed April 6, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-15 | Sale | 10b5-1 | 400 | $65.31 | 87,508 |
| 2026-09-15 | Exercise or conversion derivative | 10b5-1 | 20,000 | $0.00 | 0 |
| 2026-09-15 | Exercise or conversion | 10b5-1 | 20,000 | $17.44 | 138,016 |
| 2026-09-15 | Sale | 10b5-1 | 27,473 | $62.00 | 110,543 |
| 2026-09-15 | Sale | 10b5-1 | 20,735 | $62.61 | 89,808 |
| 2026-09-15 | Sale | 10b5-1 | 1,900 | $63.69 | 87,908 |
| 2026-09-02 | Sale | — | 642 | $66.37 | 118,016 |
| 2026-05-06 | Sale | 10b5-1 | 310 | $43.95 | 118,658 |
The 8 most recent of 17 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Travere Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,181,250 | $5,194,652 | $72,813 | $6,521,407 |
| Involuntary termination without cause | $787,500 | $2,837,790 | $48,542 | $3,746,524 |
| Death | — | $0 | — | $335,192 |
| Disability | $525,000 | $2,837,790 | $48,542 | $3,746,524 |
Per the Potential Payments Upon Termination or Change in Control table in Travere Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Travere Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $8,457,151 |
| Jula Inrig | Chief Medical Officer | $3,041,632 |
| Peter Heerma | Chief Commercial Officer | $2,261,751 |
| William Rote | Chief Research Officer | $2,256,465 |
| Christopher Cline · this page | Chief Financial Officer | $2,250,914 |
The full Travere Therapeutics compensation record
free company briefThis page is one person within Travere Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Travere Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Travere Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat